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Breast cancer is characterised by an elevated capacity for tumour invasion and lymph node metastasis, but the
cause remains to be determined. Recent studies suggest that microRNAs can regulate the evolution of malignant
behaviours by regulating multiple target genes. In this study, we have first confirmed that miR-639 is up-regulated
in metastatic breast cancer tissues and cell line with highly invasive capacity. Furthermore, we provided evidence to
demonstrate that up-regulation of miR-639 contributes breast cancer invasion and metastasis. These data reveal a
key role of miR-639 in breast cancer metastasis and support biological and clinical links between miR-639 and breast
cancer.
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Breast cancer-related deaths are caused by cancer metas-
tases rather than the primary tumor. Different subtypes
of breast cancer exhibit distinct metastases behaviors in
terms of the temporal kinetics and anatomic sites. Estro-
gen receptor–positive (ER+) breast cancer, predomin-
antly recurs in bone after the diagnosis of the primary
tumor [1]. The main mechanisms underlying these ob-
servations, however, remain to be elucidated.
MicroRNAs (miRNAs) are small, endogenous, non-
coding RNAs which play important gene-regulatory roles
in animals via sequence-specific interactions with the 3′
UTR of cognate mRNA targets, causing suppression of
translation and mRNA decay [2]. It has been firmly estab-
lished that miRNAs regulate many key cellular processes
such as cell growth, differentiation and apoptosis [3,4].
About 50% of annotated human miRNAs are detected in
regions of fragile sites, which are associated with cancer.
Experiments have confirmed that miRNAs participate in
the tumorigenesis progression of many types of cancers,
including the breast cancer [5]. Although the number of
verified human miRNAs is still expanding, the functions
of only a few have been described. Subsets of miRNAs
have been identified as potential diagnostic and prognostic* Correspondence: xinguangqiu@126.com
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unless otherwise stated.markers in malignant tumors [6-8]. MiR-639 has been
reported to have disrupted expression in pathological
states [9,10]. Similarly, miR-639 has been proven to be
dysregulated in in serum of patients with bladder cancer.
Therefore, the role of miR-639 in breast cancer caused us
a great interest.
In this study, we examined the expression of miR-639
in breast cancer tissue samples and breast cancer cell
lines. We found that miR-639 levels were up-regulated
in metastatic breast cancer tissues and highly invasive
cell lines. Furthermore, we have investigated the mech-
anism of miR-639 in breast cancer cell lines. These re-
sults show that exogenous overexpression of miR-639
promotes the invasion and migration of breast cancer
cells in vitro.Materials and methods
Cell culture
MCF-7 cancer cells are breast cancer derived and display
an epithelial phenotype and low invasive capacity. MDA-
MB-231 (MD231) cancer cells are also breast cancer de-
rived but these cells have a mesenchymal phenotype and
high invasive capacity. Both these breast cancer cell lines
were obtained from the American Type Culture Collec-
tion (ATCC). These cell lines were cultured in DMEM
supplemented with 10% heat-inactivated FBS (GIBCO
BRL, NY, USA), penicillin (100 units/ml) and streptomycin
(100 μg/ml) at 37°C in a humidified 5% CO2 atmosphere.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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All samples were obtained by surgery and quickly frozen in
liquid nitrogen and stored at −80°C. Informed consent was
obtained in advance for all patients selected in this study. In
parallel, a separate cohort of 84 patients was assembled
from a large pool of patients in the database based on histo-
logical diagnosis of breast cancer between 2001 and 2005.
We retrospectively reviewed the medical records of patients.
Total RNAs were extracted from paraffin blocks using the
high pure miRNA isolation kit according to the manufac-
turer’s protocol (Roche, Switzerland) before further analysis.
Both the miR-639 inhibitor and its mimics were pur-
chased from GenePharma (Shanghai, China). The high
pure miRNA isolation kit was purchased from Roche
(Basel, Switzerland). The miRcute miRNA qPCR detec-
tion kit and miRcute miRNA qPCR detection kit were
purchased from TIANGEN BIOTECH (Beijing, China).
Real-time PCR analysis
Real-time PCR reactions were performed using an ABI
7500 real-time PCR system (Applied Biosystems, CA). Re-
verse transcription of the extracted miRNA was performed
with miRNA-specific primers using the miRcute miRNA
first-strand cDNA synthesis kit, and real-time PCR of
miRNAs was performed using the miRcute miRNA qPCR
detection kit according to the manufacturer’s protocol
(TIANGEN BIOTECH, China), the primer is provided by
the miRcute miRNA qPCR detection kit.
Invasion assays and wound-healing experiment
In vitro invasion assays, a total of 4 × 104 cells in 200 μl
serum-free DMEM medium were plated onto BD BioCoat™
Matrigel™ Invasion Chambers (8 μm pore size; BD Biosci-
ences), and the lower chamber was immediately filled with
500 μl of DMEM medium with 10% FBS as a chemo-
attractant. After 24 hrs of incubation in a humidified at-
mosphere containing 5% CO2 at 37°C, the membranes
were then fixed with methanol and stained by 0.2% crystal
violet. For wound-healing experiments, cells were plated
in 6-well plates, transfected as indicated, and cultured toFigure 1 Clinical association of miR-639 with metastases in breast can
samples by real-time PCR. (B) Kaplan-Meier graph representing the probabilit
dataset stratified. The log-rank test P value reflects the significance of the assoconfluency. Cells were serum-starved and scraped with a
P200 tip (time 0), and pictures (5 fields) were taken at the
24 h time points.
Informed consent and ethical approval
This study was approved by Institutional Ethic Committee
Office of the First Affiliated Hospital of Zhengzhou
University. Written informed consent was obtained from
the patient for the publication of this article and accom-
panying images.
Statistical analysis
The categorical variables were compared among the
groups using the X-squared test. The continuous variables
were analyzed using the two-tailed Student’s t-test. A P
value of <0.05 was considered statistically significant.
Results
The association of miR-639 expression with metastatic
rates in patients with breast cancer
We first measured mature miR-639 levels in a group of
tissue specimens from breast cancer patients. In the 82
metastatic breast cancer tissues, the expression level of
miR-639 was 2.11 ± 0.31, whereas its expression level in
the 76 tissues with non-metastatic breast cancer tissues
was 1.19 ± 0.14 (P = 0.024; Figure 1A). These results
showed that miR-639 expression levels in primary meta-
static breast cancer tissues samples were significantly higher
than those non-metastatic breast cancer tissues. The corre-
lations between miR-639 expression levels and clinical
pathological characteristics are summarised in Table 1. Sta-
tistically significant reverse associations between miR-639
expression levels and metastatic rates were observed. In the
74 breast cancer tissues with severe histological signs, the
expression level of miR-639 was 1.73 ± 0.17, which was also
significantly higher than the expression level of 1.57 ± 0.23
in 77 tissues with non-histological signs (P = 0.038; Table 1).
We next analyzed mature miR-639 levels in the collec-
tion of breast cancer patients with clinical characteristics.
Patients were divided into two groups with high or lowcer patients. (A) Mature miR-639 levels were measured in breast cancer
y of disease-free survival in breast cancer patients from the “Milan-INT”
ciation between low miR-639 level and disease-free survival.
Table 1 Associtions between miR-639 and clinical
parameters (n = 158)
Characteristic No. of patients miR-639 ΔCta P
No. % Mean ± SD
Age, years
≥60 69 43.7 1.71 ± 0.17 0.664
<60 89 56.3 1.64 ± 0.21
Pathologe grade
I 56 35.4 1.69 ± 0.21
II 49 31.0 1.86 ± 0.14 0.089
III 53 33.5 1.98 ± 0.15
T stage
T1 57 36.1 1.54 ± 0.27 0.471
T2 50 31.6 1.65 ± 0.24
T3 51 32.3 1.33 ± 0.17
M stage
M0 76 48.1 1.19 ± 0.14 0.024
M1 82 51.9 2.11 ± 0.31
Histologic signs of severity
(vascular emboli, perineural
invasion, diffuse infiltration)
None 77 48.7 1.57 ± 0.23 0.038
Presence 74 46.8 1.73 ± 0.17
Missing 7 4.4
Smoking history
Nonsmoker 111 70.3 1.37 ± 0.23 0.625
Smoker 39 24.7 1.47 ± 0.21
Missing 8 5.1
Alcohol history
Nondrinker 107 67.7 1.35 ± 0.29 0.225
Drinker 42 26.6 1.27 ± 0.36
Missing 9 5.7
Abbreviations: SD standard deviation, T tumor stage, N lymphnode stage.
aΔCt indicates the difference in the cycle number at which a sample’s
fluorescent signal passes a given threshold above baseline (Ct) derived from a
specific gene compared with that of U6 in tumor tissues.
Li et al. Cancer Cell International 2014, 14:39 Page 3 of 5
http://www.cancerci.com/content/14/1/39levels of miR-639. Remarkably, when tested using the
Kaplan-Meier survival analysis, the miR-639 “low expres-
sion” group displayed a significantly longer disease-free
survival rates when compared to the “high expression”
group (Figure 1B). These data suggest a possible link be-
tween miR-639 expression and breast cancer progression.
miR-639 promotes cell proliferation
MCF-7 cancer cells are breast cancer derived and display
an epithelial phenotype and low invasive capacity. MD231
cancer cells are also breast cancer derived but these cells
have a mesenchymal phenotype and high invasive capacity
and contained a relatively high level ofmiR-639 (Figure 2A).First, we assessed the growth of miR-639-transfected and
miR-NC-transfected MCF-7 cells after transient transfec-
tion. As shown in Figure 2B, miR-639 was able to increase
the proliferation of miR-639-transfected cells compared
with miR-NC-transfected cells significantly at day 3 and 5
(P < 0.05, Student’s t-test). We further tested if endogenous
expression of miR-639 was required for breast cancer cell
invasion in the higher metastatic cancer cell line MD231.
For this purpose, we silenced miR-639 and this treatment
led to an approximately 2-fold decline in growth properties
(Figure 2C).
Ectopic expression of miR-639 promotes cancer metastasis
In light of the preceding data, we aimed to determine
more directly if miR-639 plays a causal role in the ag-
gressive traits of breast cancer cells. MCF-7 cancer cells
display an epithelial phenotype and low invasive capacity
and MD231 cancer cells have a mesenchymal phenotype
and high invasive capacity. We used these cell lines to
investigate how gain or loss of function of miR-639 im-
pacted cell migration and invasion, which are hallmarks
of metastatic capacity. The MD231 cells displayed high
migration capacities and contained a relatively high level
of miR-639 (Figure 2A). In the transwell assays shown in
Figure 3B, down regulation of miR-639 in MD231 cells
decreased invasive abilities 3-fold compared to the same
cells expressing miR-NC. We further tested if endogen-
ous expression of miR-639 was required for cell invasion
in the lower metastatic cancer cell line MCF-7. For this
purpose, we upregulated miR-639 and this treatment led
to an approximately 2-fold augmentation in invasive
properties (Figure 3A). Furthermore, the pro-migration
effects of miR-639 were observed in wound-healing as-
says in MCF-7 and MD231 cells (Figure 3C and D).
Discussion
Although a global reduction of miRNA abundance ap-
pears to be a general trait of human cancers, playing a
causal role in the metastatic phenotype [11-13], several
miRNAs are up-regulated in tumors [14], Recently, miR-
NAs have been shown to be related to tumor metastasis
[15], providing a new perspective on the metastatic
process. Nonetheless, The role of miRNAs in breast can-
cer has been widely investigated. Here, we will focus on
miRNA-639 promotes breast cancer metastasis.
In this study, we described for the first time the miR-
639 is markly upregulated in metastatic breast cancer in
large samples. We also found that miR-639 is closely re-
lated to the cancer metastasis and miR-639 “high expres-
sion” group displayed a significantly poorer disease-free
survival rates. We have proven that the down-regulation
of miR-639 is crucial in breast cancer metastasis and
demonstrated that miR-639 acts as a putative oncogene.
MD231 cells, which stably express miR-639 ectopically,
Figure 2 miR-639 promotes breast cancer cell proliferation. (A) Expression levels of miR-639 in cellular models of metastatic progression were
tested by real-time PCR. Values related to the nonmetastatic, less aggressive cell line (MCF-7) are normalised to U6 and shown as the mean and
SD. (B and C) Cell growth curves: proliferation of phenotypically stable indicated cell lines was monitored by the CCK-8 assay.
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and MCF-7 cells were transfected with miR-639 mimics.
This could be in line with the internal environment of
the cells.
The genetic and epigenetic silencing of tumor suppres-
sor genes is considered a vital molecular event in theFigure 3 miR-639 promotes cell invasion and migration. (A and B) Rep
crystal violet, and taken at the same magnification and absolute quantificat
Wound-healing assay showing that gain of miR-639 promotes cell migratiodevelopment and progression of breast cancer [16]. This
study first proves that miR-639 is up-regulated in meta-
static breast cancer. Aberrant patterns of miRNA ex-
pression are implicated in human diseases including
breast cancer. Recent studies have identified miRNAs
regulated by estrogens in human breast cancer cells,resentative pictures of cells migrated through the filter, stained with
ions as cells that had invaded through the transwell. (C and D)
n and loss of miR-639 supresses cell migration.
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muscle cells, rat mammary gland, and mouse uterus.
The decline of estradiol levels in postmenopausal women
has been implicated in various age-associated disorders
[17]. The role of estrogen- regulated miR-639 expres-
sion has yet to be explored. As miRNAs function
mainly through the inhibition of target genes and Wu
et al. [18] showed p21Cip1/Waf1 expression was re-
duced by miR-639. This result may preliminary explain
the mechanism of miR-639.
Conclusion
In conclusion, our results have proven that miR-639
plays a causal role in the metastases of breast cancer.
These findings have implications for understanding the
mechanism of breast cancer metastasis, and miR-639
may be a valuable maker and target for prevention or
adjuvant therapy in breast cancer patients.
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